Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists

Thomas S J Crabtree; Karen Adamson; H Reid; DJ Barnes; Siva Sivappriyan; A Bickerton; Ian W Gallen; Benjamin C. T. Field; IH Idris; Robert E J Ryder; ABCD Semaglutide Audit Contributors

doi:10.1111/dom.14701

Back

Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists

Journal article

Open access

Peer reviewed

Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists

Thomas S J Crabtree, Karen Adamson, H Reid, DJ Barnes, Siva Sivappriyan, A Bickerton, Ian W Gallen, Benjamin C. T. Field, IH Idris, Robert E J Ryder, …

Diabetes, Obesity and Metabolism, Vol.24(7), pp.1398-1401

07/2022

DOI: https://doi.org/10.1111/dom.14701

PMID: 35322528

Abstract

Diabetes Mellitus, Type 2 - drug therapy

Drug Substitution

Glucagon-Like Peptide-1 Receptor - agonists

Glucagon-Like Peptides - administration & dosage

Glucagon-Like Peptides - adverse effects

Glycated Hemoglobin A - analysis

Humans

Hypoglycemic Agents - administration & dosage

Hypoglycemic Agents - adverse effects

Liraglutide - administration & dosage

Liraglutide - adverse effects

Weight Loss

GLP-1 analogue

observational study

type 2 diabetes

The ABCD semaglutide audit was designed to capture the routine clinical outcomes of people commenced on semaglutide in the UK. Previous work showed differential reductions in HbA1c and weight dependent on previous glucagon-like peptide-1 receptor agonist (GLP-1RA) exposure. The analysis, in this research letter, shows that decreases in HbA1c and weight associated with semaglutide occur irrespective of previous GLP-1RA use. However, HbA1c reductions were less if switched from dulaglutide or liraglutide and weight changes were attenuated if switched from dulaglutide or exenatide, potentially suggesting differing potencies between GLP-1RAs. Dedicated studies with head-to-head comparisons are needed to confirm these findings.

Files and links (1)

url

https://doi.org/10.1111/dom.14701View

Published (Version of record)CC BY-NC V4.0, Open

Metrics

48 Record Views

6 Times Cited - Web of Science

See more details

Details

Title: Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists
Creators: Thomas S J Crabtree (Corresponding Author) - Royal Derby Hospital, University Hospitals of Derby and Burton NHS Trust, Derby, UK
Karen Adamson (Author) - St John's Hospital, Livingston, UK
H Reid (Author) - St John's Hospital, Livingston, UK
DJ Barnes (Author) - Maidstone and Tunbridge Wells NHS Trust, Kent, UK
Siva Sivappriyan (Author) - Maidstone and Tunbridge Wells NHS Trust, Kent, UK
A Bickerton (Author) - Yeovil District Hospital NHS Trust, Yeovil, UK
Ian W Gallen (Author) - Royal Berkshire Hospitals NHS Trust, Reading, UK
Benjamin C. T. Field (Author)
IH Idris (Author) - Royal Derby Hospital, University Hospitals of Derby and Burton NHS Trust, Derby, UK
Robert E J Ryder (Author) - City Hospital, Sandwell & West Birmingham Hospitals NHS Trust, Birmingham, UK
ABCD Semaglutide Audit Contributors (Author)
Publication Details: Diabetes, Obesity and Metabolism, Vol.24(7), pp.1398-1401
Date published: 07/2022
Date accepted: 22/03/2022
Grants: Novo Nordisk (Denmark, Copenhagen)
Grant note: The ABCD semaglutide audit is supported by an unrestricted grant from NovoNordisk.
Identifiers: 99696065902346
Copyright: © 2022 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Academic Unit: School of Biosciences
Language: English
Resource Type: Journal article

Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists

Abstract

Files and links (1)

Metrics

Details

Usage Policy